Company intelligence / Profile preview
Samaritan Biologics
- Ownership
- Private
- Development stage
- Commercial
Overview
Samaritan Biologics is conducting clinical trials evaluating the efficacy of perinatal tissue allografts in improving healing rates for chronic, non-healing diabetic foot ulcers. The main study compares these products plus standard of care versus standard of care alone over 12 weeks. As of March 2025, at least one multicenter randomized controlled trial is not yet recruiting.
- Therapeutic areas
- OtherDermatologyEndocrinology
- Modalities
- Human amniotic allograft productsPerinatal tissue allografts
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Samaritan Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Samaritan Biologics.